Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten, Jona; De Brouwer, Wouter; Kabongo, Emmanuelleet al.
2021 • In The Journal of molecular diagnostics : JMD, 23 (5), p. 599-611
[en] Detection of minimal residual disease (MRD) to guide therapy has been a standard practice in treatment of childhood acute lymphoblastic leukemia (ALL) for decades. In multiple myeloma (MM), a clear correlation is found between absence of MRD and longer survival. Quantitative allele-specific oligonucleotide (qASO)-PCR is the standard molecular method for MRD detection in these hematologic malignant tumors. However, this technique has some drawbacks that can be overcome by next-generation sequencing (NGS). In this study, NGS is validated as an alternative method for qASO-PCR for MRD detection in both ALL and MM. MRD results obtained by NGS and qASO-PCR were compared in 59 and 39 bone marrow samples of 33 and 14 patients with ALL and MM, respectively. Our results indicate that the use of gBlocks as calibrators makes the NGS approach a powerful tool to quantify MRD. With an input of 400 ng of DNA (corresponding to approximately 7 × 10(4) cells), a limit of detection of 0.01% can be achieved. The specificity of the NGS-MRD technique was 100%, and a correlation with qASO-PCR for quantifiable MRD results of 0.93 and 0.91 was found in ALL and MM, respectively. Especially for MM, the higher applicability (100%) of the NGS-MRD protocol, compared with qASO-PCR (57%), was clearly demonstrated. These results demonstrate that NGS is an even better alternative to qASO-PCR.
Disciplines :
Pediatrics Oncology Hematology
Author, co-author :
Van der Straeten, Jona
De Brouwer, Wouter
Kabongo, Emmanuelle
Dresse, Marie-Françoise ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie immuno-hémato-oncologique
Fostier, Karel
Schots, Rik
Van Riet, Ivan
Bakkus, Marleen
Language :
English
Title :
Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Deininger, M., Buchdunger, E., Druker, B.J., The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005), 2640–2653.
O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J.L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J.M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A.E., Capdeville, R., Druker, B.J., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003), 994–1004.
Hunger, S.P., Mullighan, C.G., Acute lymphoblastic leukemia in children. N Engl J Med 373 (2015), 1541–1552.
Palumbo, A., Anderson, K., Multiple myeloma. N Engl J Med 364 (2011), 1046–1060.
Kumar, S.K., Rajkumar, S.V., The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 15 (2018), 409–421.
Della Starza, I., Chiaretti, S., De Propris, M.S., Elia, L., Cavalli, M., De Novi, L.A., Soscia, R., Messina, M., Vitale, A., Guarini, A., Foà, R., Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Front Oncol, 9, 2019, 726.
Kumar, S., Paiva, B., Anderson, K.C., Durie, B., Landgren, O., Moreau, P., et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17 (2016), e328–e346.
Schrappe, M., Hunger, S.P., Pui, C.-H., Saha, V., Gaynon, P.S., Baruchel, A., Conter, V., Otten, J., Ohara, A., Versluys, A.B., Escherich, G., Heyman, M., Silverman, L.B., Horibe, K., Mann, G., Camitta, B.M., Harbott, J., Riehm, H., Richards, S., Devidas, M., Zimmermann, M., Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366 (2012), 1371–1381.
Yeoh, A.E.J., Ariffin, H., Chai, E.L.L., Kwok, C.S.N., Chan, Y.H., Ponnudurai, K., Campana, D., Tan, P.L., Chan, M.Y., Kham, S.K.Y., Chong, L.A., Tan, A.M., Lin, H.P., Quah, T.C., Minimal residual disease–guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study. J Clin Oncol 30 (2012), 2384–2392.
Pieters, R., de Groot-Kruseman, H., Van der Velden, V., Fiocco, M., van den Berg, H., de Bont, E., Egeler, R.M., Hoogerbrugge, P., Kaspers, G., Van der Schoot, E., De Haas, V., Van Dongen, J., Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol 34 (2016), 2591–2601.
Borowitz, M.J., Wood, B.L., Devidas, M., Loh, M.L., Raetz, E.A., Salzer, W.L., Nachman, J.B., Carroll, A.J., Heerema, N.A., Gastier-Foster, J.M., Willman, C.L., Dai, Y., Winick, N.J., Hunger, S.P., Carroll, W.L., Larsen, E., Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood 126 (2015), 964–971.
Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N., Camitta, B.M., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111 (2008), 5477–5485.
Conter, V., Bartram, C.R., Valsecchi, M.G., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Arico, M., Zimmermann, M., Mann, G., De Rossi, G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Barisone, E., Henze, G., Ludwig, W.-D., Haas, O.A., Cazzaniga, G., Koehler, R., Silvestri, D., Bradtke, J., Parasole, R., Beier, R., van Dongen, J.J.M., Biondi, A., Schrappe, M., Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 Study. Blood 115 (2010), 3206–3214.
van Dongen, J.J.M., van der Velden, V.H.J., Brüggemann, M., Orfao, A., Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125 (2015), 3996–4009.
Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A.V., Wade, R., Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 15 (2014), 809–818.
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Richards, S., Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 14 (2013), 199–209.
Pui, C.-H., Campana, D., Pei, D., Bowman, W.P., Sandlund, J.T., Kaste, S.C., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Kun, L.E., Jeha, S., Cheng, C., Howard, S.C., Simmons, V., Bayles, A., Metzger, M.L., Boyett, J.M., Leung, W., Handgretinger, R., Downing, J.R., Evans, W.E., Relling, M.V., Treating childhood acute lymphoblastic leukemia without Cranial Irradiation. N Engl J Med 360 (2009), 2730–2741.
Coebergh, J.W.W., Reedijk, A.M.J., de Vries, E., Martos, C., Jakab, Z., Steliarova-Foucher, E., Kamps, W.A., Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997: report from the Automated Childhood Cancer Information System project. Eur J Cancer 42 (2006), 2019–2036.
Bhojwani, D., Wayne, A.S., Acute lymphoblastic leukemia. Rodgers, G.P., Young, N.S., (eds.) The Bethesda Handbook of Clinical Hematology, ed 4, 2018, Lippincott Williams & Wilkins, Philadelphia, PA, 168.
Campana, D., Pui, C.-H., Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia. Blood 129 (2017), 1913–1918.
Bradstock, K.F., Janossy, G., Tidman, N., Papageorgiou, E.S., Prentice, H.G., Willoughby, M., Hoffbrand, A.V., Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 5 (1981), 301–309.
Landgren, O., Devlin, S., Boulad, M., Mailankody, S., Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant 51 (2016), 1565–1568.
Munshi, N., Avet-Loiseau, H., Rawstron, A.C., Owen, R., Child, J., Thakurta, A., Sherrington, P., Samur, M., Georgieva, A., Anderson, K.C., Gregory, W.M., Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 3 (2017), 28–35.
van der Velden, V.H.J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E., van Dongen, J.J.M., Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 5 (2007), 604–611.
Kotrova, M., van der Velden, V.H.J., van Dongen, J.J.M., Formankova, R., Sedlacek, P., Bruggemann, M., Zuna, J., Stary, J., Trka, J., Fronkova, E., Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transplant 52 (2017), 962–968.
Fronkova, E., Muzikova, K., Mejstrikova, E., Kovac, M., Formankova, R., Sedlacek, P., Hrusak, O., Stary, J., Trka, J., B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant, 42, 2008, 187.
Kotrova, M., Muzikova, K., Mejstrikova, E., Novakova, M., Bakardjieva-Mihaylova, V., Fiser, K., Stuchly, J., Giraud, M., Salson, M., Pott, C., Brüggemann, M., Füllgrabe, M., Stary, J., Trka, J., Fronkova, E., The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood 126 (2015), 1045–1047.
van Dongen, J.J.M., Lhermitte, L., Bottcher, S., Almeida, J., van der Velden, V.H.J., Flores-Montero, J., Rawstron, A., Asnafi, V., Lecrevisse, Q., Lucio, P., Mejstrikova, E., Szczepanski, T., Kalina, T., de Tute, R., Brüggemann, M., Sedek, L., Cullen, M., Langerak, A.W., Mendonca, A., Macintyre, E., Martin-Ayuso, M., Hrusak, O., Vidriales, M.B., Orfao, A., EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26 (2012), 1908–1975.
Theunissen, P., Mejstrikova, E., Sedek, L., van der Sluijs-Gelling, A.J., Gaipa, G., Bartels, M., Sobral da Costa, E., Kotrová, M., Novakova, M., Sonneveld, E., Buracchi, C., Bonaccorso, P., Oliveira, E., Te Marvelde, J.G., Szczepanski, T., Lhermitte, L., Hrusak, O., Lecrevisse, Q., Grigore, G.E., Buracchi, C., Bonaccorso, P., Oliveira, E., Te Marvelde, J.G., Szczepanski, T., Lhermitte, L., Hrusak, O., Lecrevisse, Q., Grigore, G.E., Fronkovà, E., Trka, J., Brüggeman, M., Orfao, A., van Dongen, J.J.M., van der Velden, V.H.J., Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129 (2017), 347–357.
Silvennoinen, R., Lundan, T., Kairisto, V., Pelliniemi, T.-T., Putkonen, M., Anttila, P., Huotari, V., Mäntymaa, P., Siitonen, S., Uotila, L., Penttilä, T.-L., Juvonen, V., Selander, T., Remes, K., Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J, 4, 2014, e250.
Gambella, M., Omedé, P., Spada, S., Muccio, V.E., Gilestro, M., Saraci, E., Grammatico, S., Larocca, A., Conticello, C., Bernardini, A., Gamberi, B., Troia, R., Liberati, A.M., Offidani, M., Rocci, A., Palumbo, A., Cavo, M., Sonneveld, P., Boccadoro, M., Oliva, S., Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer 125 (2019), 750–760.
Brüggemann, M., Kotrová, M., Knecht, H., Bartram, J., Boudjorgha, M., Bystry, V., et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33 (2019), 2241–2253.
Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V.H.J., Pérez-Morán, J.J., Vidriales, M.-B., García-Sanz, R., Jimenez, C., González, M., Martínez-López, J., Corral-Mateos, A., Grigore, G.E., Fluxá, R., Pontes, R., Caetano, J., Sedek, L., Del Cañizo, M.C., Bladé, J., Lahuerta, J.J., Aguilar, C., Bárez, A., García-Mateo, A., Labrador, J., Leoz, P., Aguilera-Sanz, C., San-Miguel, J., Mateos, M.V., Durie, B., van Dongen, J.J.M., Orfao, A., Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31 (2017), 2094–2103.
Lahuerta, J.J., Paiva, B., Vidriales, M.B., Cordón, L., Cedena, M.-T., Puig, N., Martinez-Lopez, J., Rosiñol, L., Gutierrez, N.C., Martín-Ramos, M.L., Oriol, A., Teruel, A.I., Echeveste, M.-A., de Paz, R., de Arriba, F., Hernandez, M.T., Palomera, L., Martinez, R., Martin, A., Alegre, A., De la Rubia, J., Orfao, A., Mateos, M.-V., Blade, J., San-Miguel, J.F., Grupo Español de Mieloma. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical Trials. J Clin Oncol 35 (2017), 2900–2910.
Martinez-Lopez, J., Lahuerta, J.J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M.A., Paiva, B., Weng, L., Jiménez, C., Sopena, M., Moorhead, M., Cedena, T., Rapado, I., Mateos, M.V., Rosiñol, L., Oriol, A., Blanchard, M.J., Martínez, R., Bladé, J., San Miguel, J., Faham, M., García-Sanz, R., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123 (2014), 3073–3079.
Takamatsu, H., Takezako, N., Zheng, J., Moorhead, M., Carlton, V.E.H., Kong, K.A., Murata, R., Ito, S., Miyamoto, T., Yokoyama, K., Matsue, K., Sato, T., Kurokawa, T., Yagi, H., Terasaki, Y., Ohata, K., Matsumoto, M., Yoshida, T., Faham, M., Nakao, S., Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol 28 (2017), 2503–2510.
Oliva, S., Gambella, M., Gilestro, M., Muccio, V.E., Gay, F., Drandi, D., Ferrero, S., Passera, R., Pautasso, C., Bernardini, A., Genuardi, M., Patriarca, F., Saraci, E., Petrucci, M.T., Pescosta, N., Liberati, A.M., Caravita, T., Conticello, C., Rocci, A., Musto, P., Boccadoro, M., Palumbo, A., Omedè, P., Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget 8 (2016), 5924–5935.
Puig, N., Sarasquete, M.E., Balanzategui, A., Martinez, J., Paiva, B., Garcia, H., Fumero, S., Jimenez, C., Alcoceba, M., Chillon, M.C., Sebastian, E., Marin, L., Montalban, M.A., Mateos, M.V., Oriol, A., Palomera, L., de la Rubia, J., Vidriales, M.B., Blade, J., Lahuerta, J.J., Gonzalez, M., Miguel, J.F.S., Garcia-Sanz, R., Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma: a comparative analysis with flow cytometry. Leukemia 28 (2014), 391–397.
Sarasquete, M.E., Garcia-Sanz, R., Gonzalez, D., Martinez, J., Mateo, G., Martinez, P., Ribera, J.M., Hernandez, J.M., Lahuerta, J.J., Orfao, A., Gonzalez, M., San Miguel, J.F., Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90 (2005), 1365–1372.
Korde, N., Roschewski, M., Zingone, A., Kwok, M., Manasanch, E.E., Bhutani, M., et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 1 (2015), 746–754.
Beillard, E., Pallisgaard, N., van der Velden, V.H.J., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J.J.M., Hokland, P., Gabert, J., Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 17 (2003), 2474–2486.
Faham, M., Zheng, J., Moorhead, M., Carlton, V.E.H., Stow, P., Coustan-Smith, E., Pui, C.-H., Campana, D., Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120 (2012), 5173–5180.
González, D., Balanzategui, A., García-Sanz, R., Gutiérrez, N., Seabra, C., van Dongen, J.J.M., González, M., San Miguel, J.F., Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. Leukemia 17 (2003), 1398–1403.
Garcia-Sanz, R., Lopez-Perez, R., Langerak, A.W., Gonzalez, D., Chillon, M.C., Balanzategui, A., Mateos, M.V., Alaejos, I., Gonzalez, M., Van Dongen, J.J.M., San Miguel, J.F., Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. Haematologica 84 (1999), 328–335.
Arcila, M.E., Yu, W., Syed, M., Kim, H., Maciag, L., Yao, J., Ho, C., Petrova, K., Moung, C., Salazar, P., Rijo, I., Baldi, T., Zehir, A., Landgren, O., Park, J., Roshal, M., Dogan, A., Nafa, K., Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of b-cell and plasma cell neoplasms. J Mol Diagn 21 (2019), 330–342.
Ladetto, M., Bruggemann, M., Monitillo, L., Ferrero, S., Pepin, F., Drandi, D., Barbero, D., Palumbo, A., Passera, R., Boccadoro, M., Ritgen, M., Gokbuget, N., Zheng, J., Carlton, V., Trautmann, H., Faham, M., Pott, C., Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 28 (2014), 1299–1307.
Giusti, G.N.N., Jotta, P.Y., Lopes C de, O., Ganazza, M.A., de Azevedo, A.C., Brandalise, S.R., Meidanis, J., Yunes, J.A., Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia. Br J Haematol 189 (2020), e150–e154.
Thörn, I., Forestier, E., Botling, J., Thuresson, B., Wasslavik, C., Björklund, E., Li, A., Lindström-Eriksson, E., Malec, M., Grönlund, E., Torikka, K., Heldrup, J., Abrahamsson, J., Behrendtz, M., Söderhäll, S., Jacobsson, S., Olofsson, T., Porwit, A., Lönnerholm, G., Rosenquist, R., Sundström, C., Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol 152 (2011), 743–753.
Jo, I., Chung, N.-G., Lee, S., Kwon, A., Kim, J., Choi, H., Jang, W., Kim, S., Lee, J.W., Yoon, J.-H., Cho, B., Han, K., Kim, Y., Kim, M., Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia. Clinica Chim Acta 488 (2019), 81–89.
Neale, G.A.M., Coustan-Smith, E., Stow, P., Pan, Q., Chen, X., Pui, C.-H., Campana, D., Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 18 (2004), 934–938.
Malec, M., van der Velden, V.H.J., Björklund, E., Wijkhuijs, J.M., Söderhäll, S., Mazur, J., Björkholm, M., Porwit-MacDonald, A., Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 18 (2004), 1630–1636.
Sala Torra, O., Othus, M., Williamson, D.W., Wood, B., Kirsch, I., Robins, H., Beppu, L., O'Donnell, M.R., Forman, S.J., Appelbaum, F.R., Radich, J.P., Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant 23 (2017), 691–696.
Romano, A., Palumbo, G.A., Parrinello, N.L., Conticello, C., Martello, M., Terragna, C., Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives. Front Oncol, 9, 2019, 699.
Paiva, B., van Dongen, J.J.M., Orfao, A., New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125 (2015), 3059–3068.
Yao, Q., Bai, Y., Orfao, A., Chim, C.S., Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. Front Oncol, 9, 2019, 449.
González, D., van der Burg, M., García-Sanz, R., Fenton, J.A., Langerak, A.W., González, M., van Dongen, J.J.M., San Miguel, J.F., Morgan, G.J., Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110 (2007), 3112–3121.
Bakkus, M., Heirman, C., Van Riet, I., Van Camp, B., Thielemans, K., Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80 (1992), 2326–2335.
Bai, Y., Wong, K.Y., Fung, T.K., Chim, C.S., High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. J Hematol Oncol, 9, 2016, 107.
Ria, R., Reale, A., Vacca, A., Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 4 (2014), 73–90.
Rustad, E.H., Hultcrantz, M., Yellapantula, V.D., Akhlaghi, T., Ho, C., Arcila, M.E., Roshal, M., Patel, A., Chen, D., Devlin, S.M., Jacobsen, A., Huang, Y., Miller, J.E., Papaemmanuil, E., Landgren, O., Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS One, 14, 2019, e0211600.
Beishuizen, A., Verhoeven, M.-A., van Wering, E.R., Hählen, K., Hooijkaas, H., van Dongen, J.J.M., Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 83 (1994), 2238–2247.
Gawad, C., Pepin, F., Carlton, V.E.H., Klinger, M., Logan, A.C., Miklos, D.B., Faham, M., Dahl, G., Lacayo, N., Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood 120 (2012), 4407–4417.
Szczepański, T., Willemse, M.J., Brinkhof, B., van Wering, E.R., van der Burg, M., van Dongen, J.J.M., Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 99 (2002), 2315–2323.
